Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...

Air pollution was cited as a key driver of this type of lung cancer, with the highest levels reported in East Asia, particularly China, the release stated. Worldwide, adenocarcinoma made up more ...

China's national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European and American approvals, following a revamp of the country's ...

China health care companies received a significant reprieve in terms of geopolitical risks when the US Senate declined to ...

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor ("TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...

Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, ...